|Bid||3.980 x N/A|
|Ask||N/A x N/A|
|Day's Range||3.900 - 4.000|
|52 Week Range||3.130 - 10.950|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 16, 2018 - Apr 20, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.58|
Glancy Prongay & Murray LLP announces an investigation on behalf of GNC Holdings, Inc. investors concerning the Company and its directors’ and officers’ possible violations of state laws.
GNC Holdings (GNC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
March 13 (Reuters) - Harbin Pharmaceutical Group Co Ltd : * SAYS IT BUYS 299,950 PREFERENCE SHARES IN GNC * SAYS CONVERSION PRICE FOR EACH PREFERENCE SHARE SET AT $5.35, CO WILL HOLD 40.1 PERCENT IN GNC ...
PITTSBURGH, March 8, 2018 /PRNewswire/ -- General Nutrition Corporation (GNC) announced plans to grow its business in India, where the company has had a presence since 2004. As part of its larger international growth strategy, GNC is working with master franchise partner, Guardian Healthcare Services Pvt. Ltd. ("Guardian"), to aggressively expand in India, from approximately 50 retail locations primarily in Guardian pharmacies, to multiple channels, encompassing retail, e-commerce and distribution, among others.
GNC Holdings Inc (NYSE:GNC) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
In addition, GNC Nutrition has cancelled its existing revolving credit facility, entered into a new $100 million ABL Revolver and a portion of the extended term loans have been exchanged for ABL FILO term loans which, together with certain newly funded ABL FILO term loans, equal $275 million in aggregate principal amount. The ABL Revolver and ABL FILO loans mature in August 2022 and December 2022, respectively, subject to certain conditions. The completion of the amendment and extension process satisfies a condition to closing of the previously announced approximately $300 million strategic investment in the Company by Harbin Pharmaceutical Group Holding Co., Ltd ("Hayao").
GNC Holdings Inc. shares jumped 5% in Friday premarket trading after the company announced an extended maturity date of term loans to March 2021, a two-year extension. With this amendment, the health and ...
PITTSBURGH, Feb. 23, 2018 /PRNewswire/ -- GNC Holdings, Inc. (GNC) (the "Company") today announced that it has received consents from approximately 87% of term lenders under GNC Nutrition Centers, Inc.'s credit agreement to extend the maturity date of the term loans held by such lenders to March 2021 and to make certain other modifications to the credit agreement. GNC also announced that Harbin Pharmaceutical Group Holding Co., Ltd ("Hayao") has agreed that, subject to closing of the amendment in accordance with the Securities Purchase Agreement between the parties, this level of participation in the amendment satisfies the minimum participation requirement in the previously announced $300 million strategic investment and that both parties will continue working together to complete the transaction.
Ailing US vitamin and supplement retailer GNC Holdings Inc has sweetened the terms of a complex amendment to its existing credit agreement to extend a looming March 2019 debt maturity, after early consents from lenders fell short of a required threshold, according to three sources familiar with the transaction. GNC launched the amendment on February 13, offering fees to lenders of its US$1.13bn leveraged loan to push out the maturity by two years to March 2021, in order to buy the company additional time to stage a turnaround. Goldman Sachs is advising on the amendment, while JP Morgan is administrative agent.
Vitamin retailer GNC Holdings has received a $300 million investment from a Chinese pharmaceutical company, a result of its recent mission to explore strategic alternatives.
Q4 2017 GNC Holdings Inc Earnings and China Joint Venture with Harbin Pharmaceutical Conference Call
GNC Holdings Inc (NYSE:GNC) has had a great year so far. After losing nearly half of its value in 2017, GNC stock has made a major comeback during the first few weeks of 2018, pushing its share price up more than 20% higher since January 1. The uptick isn’t unfounded either, GNC appears to have found a way out of its precarious, and some would say dire, financial situation.
GNC Holdings Inc (NYSE:GNC), a US$350.41M small-cap, operates in the retail industry impacted by the digital transformation for all retail channels. Physical store retailers faced the inevitable challenge of buildingRead More...
Feb 14 (Reuters) - Harbin Pharmaceutical Group Co Ltd : * SAYS CONTROLLING SHAREHOLDER SIGNS AGREEMENT TO BUY GNC HOLDINGS' CONVERTIBLE PREFERENCE SHARES WORTH $299.95 MILLION * SAYS IT SCRAPS PLAN FOR ...
Stocks that moved substantially or traded heavily on Tuesday: AmerisourceBergen Corp., up $8.32 to $97.77 The Wall Street Journal said Walgreens Boots Alliance is interested in buying the rest of the prescription ...
GNC stock rebounded in January following a favorable fourth-quarter sales preview, and recently bounced again on news of a deal to expand its operations in China.
Shares of GNC are up today thanks to a narrowing bottom-line loss and $300 million investment from a Chinese pharmaceutical company.
The new deal that has GNC stock flying high today includes a $300 million investment into the company by Harbin Pharmaceutical. This will make the Chinese company the single largest shareholder of GNC stock. GNC Holdings Inc and Harbin Pharmaceutical will also be teaming up on a new joint venture.
GNC announced a strategic partnership and joint venture agreement with China's Harbin Pharmaceutical Group. Also known as Hayao, the company will invest $300 million in GNC (GNC), a Pittsburgh-based nutrition retailing chain, and become the single largest shareholder, according to a news release. The joint venture will manufacture, market, sell and distribute GNC-branded products in China, the release said.